Cole K S, Murphey-Corb M, Narayan O, Joag S V, Shaw G M, Montelaro R C
Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
J Virol. 1998 Oct;72(10):7852-9. doi: 10.1128/JVI.72.10.7852-7859.1998.
Characterization of virus-specific immune responses to human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) is important to understanding the early virus-host interactions that may determine the course of virus infection and disease. Using a comprehensive panel of serological assays, we have previously demonstrated a complex and lengthy maturation of virus-specific antibody responses elicited by attenuated strains of SIV that was closely associated with the development of protective immunity. In the present study, we expand these analyses to address several questions regarding the nature of the virus-specific antibody responses to pathogenic SIV, SIV/HIV-1 (SHIV), and HIV-1 infections. The results demonstrate for the first time a common theme of antibody maturation to SIV, SHIV, and HIV-1 infections that is characterized by ongoing changes in antibody titer, conformational dependence, and antibody avidity during the first 6 to 10 months following virus infection. We demonstrate that this gradual evolution of virus-specific antibody responses is independent of the levels of virus replication and the pathogenicity of the infection viral strain. While the serological assays used in these studies were useful in discriminating between protective and nonprotective antibody responses during evaluation of vaccine efficacy with attenuated SIV, these same assays do not distinguish the clinical outcome of infection in pathogenic SIV, SHIV, or HIV-1 infections. These results likely reflect differences in the immune mechanisms involved in mediating protection from virus challenge compared to those that control an established viral infection, and they suggest that additional characteristics of both humoral and cellular responses evolve during this early immune maturation.
表征针对人类免疫缺陷病毒1型(HIV-1)和猴免疫缺陷病毒(SIV)的病毒特异性免疫反应,对于理解可能决定病毒感染和疾病进程的早期病毒-宿主相互作用至关重要。我们之前使用一组全面的血清学检测方法,证明了由减毒SIV毒株引发的病毒特异性抗体反应的成熟过程复杂且漫长,这与保护性免疫的发展密切相关。在本研究中,我们扩展了这些分析,以解决有关针对致病性SIV、SIV/HIV-1(SHIV)和HIV-1感染的病毒特异性抗体反应性质的几个问题。结果首次证明了针对SIV、SHIV和HIV-1感染的抗体成熟的共同主题,其特征是在病毒感染后的前6至10个月内,抗体滴度、构象依赖性和抗体亲和力持续变化。我们证明,这种病毒特异性抗体反应的逐渐演变与病毒复制水平和感染病毒株的致病性无关。虽然这些研究中使用的血清学检测方法在评估减毒SIV疫苗效力期间有助于区分保护性和非保护性抗体反应,但相同的检测方法无法区分致病性SIV、SHIV或HIV-1感染的临床结果。这些结果可能反映了介导免受病毒攻击的保护的免疫机制与控制已建立的病毒感染的免疫机制之间的差异,并且表明在这种早期免疫成熟过程中,体液和细胞反应的其他特征也在演变。